EHMT2 and triple-negative breast carcinoma: The effects on gene expression of the selective EZH2 inhibitor GSK343 [10] and the selective EHMT2 inhibitor UNC0638 [22] (Fig. 2) used alone or in combination were also examined using the MDA-MB-231 triple negative breast cancer cell line (Fig. 1b).